Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BOLTCVE:CZXTSE:FCR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBOLTBolt Biotherapeutics$5.77+2.9%$6.49$5.20▼$15.60$10.75M0.9211,177 shs23,736 shsCZXCanada Zinc MetalsC$0.31+∞C$0.31C$0.22▼C$0.39C$51.69MN/A238,645 shs118,500 shsFCRFirst Capital RealtyC$0.00C$18.60▼C$22.79N/AN/A468,009 shs3.04 million shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBOLTBolt Biotherapeutics0.00%-3.11%-8.63%-29.88%-62.60%CZXCanada Zinc Metals0.00%0.00%0.00%0.00%0.00%FCRFirst Capital Realty0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBOLTBolt Biotherapeutics3.4716 of 5 stars3.23.00.00.03.33.31.3CZXCanada Zinc MetalsN/AN/AN/AN/AN/AN/AN/AN/AFCRFirst Capital RealtyN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBOLTBolt Biotherapeutics 2.33Hold$50.00766.55% UpsideCZXCanada Zinc Metals 0.00N/AN/AN/AFCRFirst Capital Realty 4.00Strong BuyN/AN/ACurrent Analyst Ratings BreakdownLatest AVW, BOLT, CZX, and FCR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/20/2025BOLTBolt BiotherapeuticsLake Street CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$80.005/13/2025BOLTBolt BiotherapeuticsStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetHold ➝ Hold$25.00 ➝ $20.00(Data available from 6/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBOLTBolt Biotherapeutics$7.69M1.44N/AN/A$29.89 per share0.19CZXCanada Zinc MetalsN/AN/AN/AN/AN/AN/AFCRFirst Capital RealtyN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBOLTBolt Biotherapeutics-$63.12M-$33.40N/AN/AN/A-665.56%-94.51%-59.07%8/12/2025 (Estimated)CZXCanada Zinc MetalsN/AN/A0.00∞N/AN/AN/AN/AN/AFCRFirst Capital RealtyN/AN/A0.00N/AN/AN/AN/AN/AN/ALatest AVW, BOLT, CZX, and FCR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2025Q1 2025BOLTBolt Biotherapeutics-$6.80-$5.80+$1.00-$0.29$0.77 million$1.22 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBOLTBolt BiotherapeuticsN/AN/AN/AN/AN/ACZXCanada Zinc MetalsN/AN/AN/AN/AN/AFCRFirst Capital RealtyN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBOLTBolt Biotherapeutics0.483.133.13CZXCanada Zinc MetalsN/AN/AN/AFCRFirst Capital RealtyN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBOLTBolt Biotherapeutics86.70%CZXCanada Zinc MetalsN/AFCRFirst Capital RealtyN/AInsider OwnershipCompanyInsider OwnershipBOLTBolt Biotherapeutics30.90%CZXCanada Zinc MetalsN/AFCRFirst Capital RealtyN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBOLTBolt Biotherapeutics901.92 million1.33 millionNot OptionableCZXCanada Zinc Metals147,000166.73 millionN/ANot OptionableFCRFirst Capital RealtyN/AN/AN/ANot OptionableQBL, BOLT, CZX, and FCR HeadlinesRecent News About These CompaniesGot $500? 1 Real Estate Stock to Buy and Hold ForeverJune 27 at 6:28 PM | msn.comFirst Capital REIT Announces C$300 Million Offering of Series E Senior Unsecured DebenturesJune 11, 2025 | finance.yahoo.comFirst Capital REIT Gets TSX Thumbs Up To Renew Buyback of 10% of Public FloatMay 16, 2025 | marketwatch.comFirst Capital Real Estate Investment Trust to conduct normal course issuer bidMay 16, 2025 | msn.comFIRST CAPITAL REIT REPORTS SOLID FIRST QUARTER 2025 RESULTS DRIVEN BY CONTINUED STRENGTH IN LEASINGMay 8, 2025 | seekingalpha.comFirst Capital REIT reports strong Q1 2025 results with 5.3% NOI growth, 96.9% occupancy, and robust leasing activityMay 6, 2025 | retail-insider.comRBazis Buys Two-Tower Project From First Capital For $32M, Planning Third TowerApril 8, 2025 | storeys.comSCEO buying at First Capital REIT (FCR)March 5, 2025 | theglobeandmail.comFirst Capital Real Estate Investment Trust (FCXXF) Q4 2024 Earnings Call TranscriptFebruary 14, 2025 | seekingalpha.comRBC Capital Keeps Their Buy Rating on First Capital Realty (FCR.UN)February 14, 2025 | markets.businessinsider.comFirst Capital REIT reports “strong” financial resultsFebruary 11, 2025 | retail-insider.comRLearn to Evaluate (FCR.UN) using the ChartsFebruary 9, 2025 | news.stocktradersdaily.comNFirst Capital REIT Announces Date For Fourth Quarter 2024 Results Conference CallJanuary 13, 2025 | finance.yahoo.comFirst Capital REIT Announces 3.0% Distribution Increase Effective January 2025December 17, 2024 | finance.yahoo.com3 Canadian Dividend Stocks to Load Up on NowOctober 31, 2024 | msn.comFirst Capital REIT: CIBC Raises Valuation on Solid Q3 PerformanceOctober 31, 2024 | theglobeandmail.comFirst Capital REIT Announces October 2024 DistributionOctober 16, 2024 | finance.yahoo.comFirst Capital REIT Announces Date For Third Quarter 2024 Results Conference CallSeptember 30, 2024 | finance.yahoo.comDream Unlimited, Scotiabank, EQB at 52-Week Highs on NewsSeptember 19, 2024 | ca.finance.yahoo.comFC Private Equity Realty Management Corp. Responds to Melcor REIT “Take Under” Transaction:September 18, 2024 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeQBL, BOLT, CZX, and FCR Company DescriptionsBolt Biotherapeutics NASDAQ:BOLT$5.77 +0.16 (+2.85%) As of 03:58 PM EasternBolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company's lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer. It is also developing BDC-3042, an agonist antibody targeting Dectin-2 for range of tumors, such as head and neck, non-small cell lung, ovarian, triple-negative breast, and other cancer. The company has collaboration agreements with Toray Industries, Genmab A/S, Innovent Biologics, Inc., Bristol-Myers Squibb, and F. Hoffmann-La Roche Ltd; and license agreement with Stanford University. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood City, California.Canada Zinc Metals CVE:CZXC$0.31 +0.31 (+∞) As of 05/4/2018Canada Zinc Metals Corp. explores for and evaluates mineral resource properties in Canada. The company primarily explores for zinc-lead-silver base metals deposits. Its flagship property is the Akie property that consists of 46 mineral claims, which cover approximately 116 square kilometers, located in the Paleozoic Selwyn Basin, British Columbia. The company was formerly known as Mantle Resources Inc. and changed its name to Canada Zinc Metals Corp. in September 2008. Canada Zinc Metals Corp. was incorporated in 1988 and is headquartered in Vancouver, Canada.First Capital Realty TSE:FCR More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Tesla’s Robotaxi Hype Fuels Bullish Price Targets to $500 S&P 500 All-Time Highs: 5 Catalysts Driving It Higher The Top Insider Sells From Q2: Buy, Sell, or Hold? 5 High-Yielding ETFs to Buy and Hold Forever Why BigBear.ai Could Rally 100% and Catch Palantir Soon Nike Stock: The Mother of All Comebacks Might Have Just Begun EA Just Caught a Monster Upgrade: Bullish Breakout Ahead? Alphabet’s Waymo and Services Beginning to Feel the Pressure? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.